Protection Of Organs At Risk Research Articles

Effect of breathing phase number on the 4D robust optimization for pancreatic cancer intensity modulated proton therapy

PurposeRespiratory movement, as one of the main challenges in proton therapy for pancreatic cancer patients, could not only lead to harm to normal tissues but also lead to failure of the tumor control, resulting in irreversible consequences. Including respiratory movements into the plan optimization, i.e. 4D robust optimization, may mitigate the interplay effect. However, 4D robust optimization considering images of all breathing phases is time-consuming and less efficient. This work aims to investigate the effect of the breathing phase number on the 4D robust optimization for pancreatic cancer intensity modulated proton therapy (IMPT) by examining plan quality and computational efficiency.MethodsA total of 15 pancreatic cancer patients were retrospectively analyzed. In this study, both anterior-fields and posterior-fields plans were created for each patient. For each plan, six four-dimensional (4D) robust treatment planning strategies with different numbers of respiratory phases and one three-dimensional (3D) treatment plan were created. Optimization of the plans were performed on all ten phases (10phase plan), two extreme phases (2phase plan), two extreme phases plus an intermediate state (3phase plan), two extreme phases plus the 3D CT (3Aphase plan), six phases during the exhalation stage (6Exphase plan), six phases during the inhalation stage (6Inphase plan) and 3D Computed Tomography (CT) scan image (3D plan), respectively. 4D dynamic dose (4DDD) was then calculated to access the interplay effect by considering respiratory motion and dynamic beam delivery. Plan quality and dosimetric parameters for the target and organs at risk (OARs) were then analyzed.ResultsCompared to the 4D plans, 3D plan performed terribly in terms of target coverage and organs at risk. Target dose in anterior-fields plan varied slightly among all six 4D treatment planning strategies. Both the 6Exphase and 6Inphase plans demonstrated performance that was comparable to the 10phase plan in target coverage, outperforming the other five plans for anterior-fields plan. It’s basically the same for the posterior-fields plan. The six strategies showed similar OARs sparing effect for both anterior-fields and posterior-fields plan. Compared with the 10phase plan, the average decline rates of the optimization time of the six plans of 2phase, 3phase, 3Aphase, 6Exphase, 6Inphase, and 3D were 73.26 ± 6.54% vs. 74.48 ± 6.63%, 65.80 ± 7.89% vs. 65.81 ± 9.58%, 54.67 ± 11.52% vs. 65.75 ± 9.58%, 42.14 ± 13.57% vs. 39.63 ± 16.93%, 37.72 ± 11.70% vs. 40.79 ± 13.62% and 75.52 ± 8.21% vs. 80.67 ± 5.62%, respectively (anterior vs. posterior). With the decrease of the number of phases selected for optimization, the decline rates increased, while the other dosimetry parameters generally showed a deterioration trend.ConclusionIn this study, a comprehensive evaluation of six 4D robust treatment planning strategies and one 3D treatment planning strategy for pancreatic cancer patients receiving IMPT was performed. The results showed that six 4D robust optimization strategies were comparable in common posterior field therapy. 2phase and 3phase (including 3Aphase) treatment planning strategies could replace the 10phase treatment planning strategy. It should be noted that patients with large motion amplitudes should receive special attention. The dosimetric performance of the 6Exphase and 6Inphase plans closely aligned with that of the 10phase plan in anterior fields. These plans offered a feasible alternative to 10phase treatment planning strategy by reducing optimization time while maintaining dose coverage of the target and protection of OARs. This research provides guidelines to reduce optimization time and improve clinical efficiency for pancreatic cancer IMPT.

Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy

BackgroundA dosimetric evaluation is still lacking in terms of clinical target volume (CTV) omission in stage III patients treated with 4D-CT Intensity-Modulated Radiation Therapy (IMRT).Methods49 stage III NSCLC patients received 4D-CT IMRT were reviewed. Target volumes and organs at risk (OARs) were re-delineated. Four IMRT plans were conducted retrospectively to deliver different prescribed dose (74 Gy–60 Gy), and with or without CTV implementation. Dose and volume histogram (DVH) parameters were collected and compared.ResultsIn the PTV-g 60 Gy plan (PTV-g refers to the PTV generated from the internal gross tumor volume), only 5 of 49 patients had the isodose ≥ 50 Gy line covering at least 95% of the PTV-c (PTV-c refers to the PTV generated from the internal CTV) volume. When the prescribed dose was elevated to 74 Gy to the PTV-g, 33 of 49 patients could have the isodose ≥ 50 Gy line covering at least 95% of the PTV-c volume. In terms of OARs protection, the SIB-IMRT plan showed the lowest value of V5, V20, and mean dose of lung, had the lowest V55 of esophagus, and the lowest estimated radiation doses to immune cells (EDIC). The V20, V30, and mean dose of heart was lower in the simultaneous integrated boost (SIB) IMRT (SIB-IMRT) plan than that of the PTV-c 60 Gy plan.ConclusionsCTV omission was not suitable for stage III patients when the prescribed dose to PTV-g was 60 Gy in the era of 4D-CT IMRT. CTV omission plus high dose to PTV-g (74 Gy for example) warranted further exploration. The SIB-IMRT plan had the best protection to normal tissue including lymphocytes, and might be the optimal choice.

The effect of auto-planning parameter settings on the quality of automated cervical cancer plans

PurposeThis study refines the parameters of automatic planning to improve plan quality and enhance the protection of organs at risk (OARs). Materials & methods30 cases of cervical cancer underwent manual (M-VMAT) and automated VMAT planning. The automated planning used five parameters: Engine Type (Biological and Non-Biological) and Use Cold-Spot ROIs (Yes and No) were qualitative; Tuning Balance (1–100%, default: 11%), Dose Fall-off Margin (1.0–4.5 cm, default: 2.6 cm), and Hot-Spot Maximum Goal (101–110%, default: 107%) were quantitative. The original automated plans (A1-VMAT) utilized default parameters, while the adjusted automated plans (A2-VMAT) utilized modified parameters. Dosimetric parameters and plan complexities were compared among M-VMAT, A1-VMAT, and A2-VMAT. ResultsCompared to M-VMAT, the A1-VMAT underperformed in protecting OARs. However, the A2-VMAT effectively addressed this issue. When adjusting “Use Cold-Spot ROIs” to “No”, “Tuning Balance” to 100%, and “Hot-Spot Maximum Goal” to 110%, while keeping the remaining parameters at their default settings, A2-VMAT significantly improved OAR protection in this study. Compared to A1-VMAT, the A2-VMAT showed only a slight increase in bowel's Dmax (approximately 2.11%, P < 0.05), while various OARs achieving significant dose reductions. Notably, there were significant reductions (over 30%, P < 0.05) in V35, V40 of rectum, V25, V30, V35 of femoral heads, and V10, V15, V20 of kidney. Furthermore, the efficacy of these five parameters was also observed in this study. Except for Engine Type, adjustments to the other parameters impacted Conformity Index, Homogeneity Index, and maximum dose (Dmax) for the PTV. Engine Type affected the average dose to OARs, and Hot-Spot Maximum influenced the Dmax for OARs overlapping with the PTV. ConclusionThe adjusted automated plan improved plan quality compared to the original automated plan, enhancing OAR protection. The adjusted plan demonstrated lower complexity than the manual plan.

Mixed-size spot scanning with a compact large momentum acceptance superconducting (LMA-SC) gantry beamline for proton therapy

Objective. Lowering treatment costs and improving treatment quality are two primary goals for next-generation proton therapy (PT) facilities. This work will design a compact large momentum acceptance superconducting (LMA-SC) gantry beamline to reduce the footprint and expense of the PT facilities, with a novel mixed-size spot scanning method to improve the sparing of organs at risk (OAR). Approach. For the LMA-SC gantry beamline, the movable energy slit is placed in the middle of the last achromatic bending section, and the beam momentum spread of delivered spots can be easily changed during the treatment. Simultaneously, changing the collimator size can provide spots with various lateral spot sizes. Based on the provided large-size and small-size spot models, the treatment planning with mixed spot scanning is optimized: the interior of the target is irradiated with large-size spots (to cover the uniform-dose interior efficiently), while the peripheral of the target is irradiated with small-size spots (to shape the sharp dose falloff at the peripheral accurately). Main results. The treatment plan with mixed-size spot scanning was evaluated and compared with small and large-size spot scanning for thirteen clinical prostate cases. The mixed-size spot plan had superior target dose homogeneities, better protection of OAR, and better plan robustness than the large-size spot plan. Compared to the small-size spot plan, the mixed-size spot plan had comparable plan quality, better plan robustness, and reduced plan delivery time from 65.9 to 40.0 s. Significance. The compact LMA-SC gantry beamline is proposed with mixed-size spot scanning, with demonstrated footprint reduction and improved plan quality compared to the conventional spot scanning method.

Comparative Evaluation of Dosimetric Quality and Treatment Efficiency for Halcyon, TrueBeam, and TomoTherapy in Cervical-Thoracic Esophageal Cancer Radiotherapy.

This study primarily aims to investigate the suitability of Halcyon in the context of cervical-thoracic esophageal cancer by exploring the dosimetric quality and delivery efficiency of Halcyon plans with different arc configurations. Additionally, it compares these findings with the dosimetric indices and delivery efficiency of TrueBeam and TomoTherapy accelerators, focusing on their capability to optimize protection for organs at risk (OARs) while maintaining efficient treatment delivery strategies. This retrospective study involved 26 patients diagnosed with cervical-thoracic esophageal cancer, and new radiotherapy plans were created using Halcyon, TrueBeam, and TomoTherapy. Dose volume histogram (DVH) metrics and delivery efficiency for plans involving different arc numbers on Halcyon (2, 3, and 4 arcs) were compared with those from TrueBeam and TomoTherapy. T-tests were employed to evaluate differences in organ protection among the accelerators. The Halcyon plans, especially those with 4 arcs, provided superior protection for organs at risk, including the heart, lungs, and spinal cord, while maintaining excellent delivery efficiency. Compared to TrueBeam 2arc plans and TomoTherapy helical plans, Halcyon plans with 3 arcs also showed slight advantages. Although TomoTherapy offered better uniformity in dose distribution, it did not demonstrate a clear advantage over the other accelerators in terms of OAR protection or treatment efficiency. Furthermore, despite the lack of clear advantages in TrueBeam 2arc plans with flattening filter (FF), TrueBeam with flattening filter free (FFF) plans may hold potential in the treatment. Halcyon, particularly with 4 arcs, offers an optimal balance between reducing toxicity to organs at risk and maintaining treatment efficiency, making it a preferred choice in cervical thoracic esophageal cancer radiotherapy. The findings highlight the need for careful selection of radiotherapy accelerators based on specific clinical goals, with Halcyon showing potential advantages in scenarios where both treatment efficiency and OAR protection are paramount.

New method to optimize protection of the organs at risk allows to regain coverage and homogeneity in the Planning Target Volume

The construction of auxiliary structures within the Planning Target Volume (PTV) is proposed as a method to recover coverage and homogeneity, and to optimize the protection of the organs at risk (OARs) in radiotherapy treatment plans. To this purpose, it was performed the Volumetric Modulated Arc Therapy (VMAT) treatment planning of the “mock prostate” test. Three plans were optimized in the EclipseTM treatment planning system. In plan 1 (P1), it was defined an initial objective function only for the PTV. Then, the dose received by the OARs was restricted, guaranteeing the PTV level of coverage. Plan 2 (P2) used the same dose-volume objectives for the PTV as in P1, but more restrictive dose constraints were set for the OARs. From the dose distribution obtained in P2, it was built auxiliary subvolumes contained within the PTV to regain coverage and homogeneity in plan 3 (P3). To this end, it was compared the coverage (D95%), the Homogeneity Index (HI) and dose-volume histogram for the PTV, and OARs dose sparing for rectum and Bladder. P1 and P3 resulted in similar PTV coverage and HI values, however, the OARs received a lower dose in P3. Despite in P2 it was achieved a higher OARs protection, the PTV coverage and HI were considerably reduced. In this sense P3 allowed to reach the best balance between coverage, HI, and OARs protection. As a consequence of these results, it has been shown that the introduction of auxiliary structures as target subvolumes constitute a powerful and easy to implement tool in the treatment planning optimization process and can be employed in any pathology that requires VMAT.

Photon Dose Distribution Analysis Using Three-Dimensional Conformal Radiation Therapy (3DCRT) And Intensity Modulated Radiotherapy (IMRT) Techniques in Cervical Cancer Cases Based on Histogram Volume Dose Curve (DVH)

Radiotherapy is one of the effective treatment methods for cervical cancer, although it is faced with great challenges in delivering an accurate dose of radiation. The purpose of this study was to compare the effectiveness of two cervical cancer treatment techniques, namely Three-Dimensional Conformal Radiation Therapy (3DCRT) and Intensity Modulated Radiotherapy (IMRT) in terms of conformity, homogeneity, and protection of Organs at Risk (OAR). The study used primary data from DVH 3DCRT and IMRT techniques collected from 15 cervical cancer patients. Conformity index (CI) and homogeneity (HI) were evaluated, and dose at OAR was assessed according to QUANTEC rules. The results showed the average CI value for the 3DCRT technique was (96,7 ± 1,5) x 10-2, while for IMRT it was (98,8 ± 0,8) x 10-2. In addition, the average HI score for the 3DCRT technique was (9,6 ± 1,5) x 10-2, and for IMRT it was (6,8 ± 1,9) x 10-2. In the 3DCRT technique, V50 for the rectum ranges from 0 – 57%, V65 for the bladder is 0%, and V50 for the left and right femoral heads ranges from 0 – 15.92% and 0 – 10.86%. While in the IMRT technique, V50 for the rectum ranges from 0 – 40,56%, V65 for bladder is 0%, and V50 for the left and right femoral heads ranges from 0 – 0,3% and 0 – 1,05%. The results of this study showed that the IMRT technique was better and more effective in treating cervical cancer than the 3DCRT technique. The IMRT technique has a higher CI value, indicating a better level of conformity, as well as a lower HI value, signifying a higher level of homogeneity. In addition, the IMRT technique is also able to provide better OAR protection.

Novel hybrid treatment planning approach for irradiation a pediatric craniospinal axis

This study presents a new treatment planning approach merging 3D-CRT and VMAT fields into a hybrid treatment plan (HybTP), in order to achieve an optimum dose coverage of the planning target volume (PTV) and protection of OAR. Craniospinal axis irradiation (CSI) treated with 3D conformal radiotherapy (3D-CRT) is associated with high doses to the heart and eye lenses but provides better sparing of lungs and kidneys compared to volumetric modulated arc therapy (VMAT). VMAT treatment spares eye lenses and the heart, but lungs and kidneys are not as effective as 3D-CRT. Thus, a combination of both techniques (HybTP) may be optimal in sparing all these organs at risk (OAR). The results of HybTP are compared with helical tomotherapy (HT), intensity modulated radio therapy (IMRT), VMAT, and 3D-CRT plans. Hybrid, HT, VMAT, IMRT, and 3D-CRT treatment plans for a male child (age 6 years) with medulloblastoma were created and compared. A total dose of 35.2 Gy (PTV) with a dose per fraction of 1.6 Gy was prescribed. The following dose acceptance criteria were defined:(1)Mean PTV dose should be 100% of the prescribed dose, while the maximum dose should not exceed 107%.(2)At least 98% of the PTV should receive 95% of the prescribed dose.(3)The cribriform plate should be covered by the 95% isodose line.(4)The acceptance criteria for the OARs were: lenses Dmax<10 Gy, lungs Dmean<7 Gy, kidneys Dmean<15 Gy, heart Dmean<26 Gy, and heart V25<10%.The plans were compared regarding dose homogeneity index (HI) and conformity index (CI), PTV coverage, (particularly at cribriform plate) and doses at OARs. Best conformity was achieved with HT (CI = 0.98) followed by VMAT (CI = 0.96), IMRT (CI = 0.91), HybTP (CI = 0.86), and 3D-CRT (CI = 0.83). The homogeneity index varied marginally. For both HT and IMRT the HI was 0.07, and for 3D-CRT, VMAT and HybTP the HI was between 0.13 and 0.15. The cribriform plate was sufficiently covered by HybTP, VMAT, and 3D-CRT. The dose acceptance criteria for OARs were met by HT and HybTP. VMAT did not meet the criteria for lung (Dmean = right 10.4 Gy/left 10.2 Gy), 3D-CRT did not meet the criteria for eye lenses (Dmax = right 32.3 Gy/left 33.1), and heart (V25≈44%) and IMRT did not meet the criteria for lung (Dmean = right 11.1 Gy/left 11.2 Gy) and eye lenses (Dmax = right 12.2 Gy/left 13.1). HybTP meets all defined acceptance criteria and has proved to be a reasonable alternative for CSI. With HybTP that combines VMAT at the brain and heart with 3D-CRT posterior spinal fields (to spare lungs and kidneys), both appropriate coverage of the PTV and sparing of OAR can be achieved.

Study on Dosimetric Superiority of Forward Planned Intensity-Modulated Radiotherapy Treatment of Thoracic Esophageal Squamous Cell Carcinoma

Aim and Objectives: The study was conducted to to compare the dosimetric superiority between the Field in Field and Box techniques. Meterials and Methods: We have taken 22 Patients of Ca esophagus for our study from our Institute database. Patients were already treated Box (4 fields) plan. Retrospectively additional Field in Field (FIF) plan was created with Planning target volume (PTV) prescription dose of 59.4Gy in 33 fractions. Prescription dose of 95% of PTV was chosen for the comparison between two treatment planning strategies. The Dose volume histogram (DVH) was used to analyze and compare various plan quality index and doses to the organs at risk (OARs). For each patient, two treatment plans were created: Box 4FB and FIF. The parameters compared included the conformity index (CI), homogeneity index (HI), Conformation number (CN), DMean, DMax, V20Gy and V30Gy of the heart and lungs, and monitor units per fraction (MU/fr). Results: A paired t-test analysis significant differences (P < 0.05) between the two techniques in terms of the CI, HI, and CN when the FIF was applied. The Dmax of the PTV, lung, and spinal cord were also significantly better with the FIF. Moreover, the V20Gy of the significantly reduced when the FIF was used and the MU/fr was significantly decreased. The FIF technique enables better dose distribution in the PTV and reduces dose to OARs in esophageal radiotherapy. Conclusion: Although all plans were within acceptable limits, dosimetric comparison of different planning techniques revealed that FIF had statistically significant differences from Box planning technique in terms of planned target volume (PTV) coverage, OAR protection, HI, CI, CN, MU and treatment duration. From the aspect of treatment duration and MU parameters, FIF technique can be considered as an alternative planning option.

Dosimetric Implications of Margin-Reduced MRI-Guided Stereotactic Body Radiotherapy to the Prostate Bed Following Radical Prostatectomy: Post-Hoc Analysis of a Phase II Study

<h3>Purpose/Objective(s)</h3> Due to the highly deformable and mobile nature of the target volume and adjacent organs at risk (OARs), generous planning target volume (PTV) margins have historically been used in the context of radiotherapy after radical prostatectomy. MRI-guided radiotherapy systems have improved on-board imaging capabilities and the ability to perform automatic beam holds based on pre-specified structures. Herein, we evaluate the dosimetric implications of interfraction variations in the clinical target volumes (CTV) and OARs in patients receiving margin-reduced MRI-guided stereotactic body radiotherapy (SBRT) to the prostate bed. <h3>Materials/Methods</h3> 31 consecutive patients received MRI-guided SBRT to the prostate bed (30 – 34 Gy in 5 fractions) without adaptive planning on a phase II study. The OAR volumes, CTV, and PTV (created using a 3 mm isotropic expansion of the CTV) were retrospectively contoured on on-board 0.35T MRIs obtained prior to each fraction (n=155). Geometric comparisons were made between the initial planning contours and the 5 daily contours for each patient using change in volume and Dice similarity coefficient (DSC) calculations. Coverage of the CTV and PTV was assessed (CTV V95% >93% and PTV V95% >90%), as were bladder and rectal dose constraints (Bladder Dmax <36.7 Gy, Bladder V32.5 Gy <35%, Rectum Dmax <36.7 Gy, Rectum V27.5 Gy <45%, Rectum 32.5 Gy <30%, and Rectal Wall V24 <50%). <h3>Results</h3> The median change in volume was -24.5% (interquartile range [IQR], -35.5 – -2.2%) for the bladder, 6.95% (IQR, -6.94 – 23.0%) for the rectum, -0.2% (IQR, -8.3 – 8.7%) for the rectal wall, 0.48% (IQR, -3.87 – 7.6%) for the CTV, and -0.48% (IQR, -5.12 – 6.53%) for the PTV. The median DSC was 0.79 (IQR, 0.73 – 0.84) for the bladder, 0.76 (IQR, 0.69 – 0.81) for the rectum, 0.35 (IQR, 0.28 – 0.44) for the rectal wall, 0.89 (IQR, 0.83 – 0.93) for the CTV, and 0.90 (IQR, 0.87 – 0.95) for the PTV. 145/155 fractions (93.5%) met the CTV V95% >93% target and 134/155 fractions (86.5%) met both the CTV V95% >93% and PTV V95% >90% targets. When calculated over 5 cumulative fractions, 29/31 patients (93.5%) met the CTV goal of V95% >93%. 62/155 fractions (40%) failed at least one OAR constraint. The mean number of fractions per patient that failed at least one OAR constraint was 2/5 (median, 1; range, 0 – 5). <h3>Conclusion</h3> With MRI-guidance, a reduction of the PTV margin to 3 mm isotropically allows for adequate CTV coverage in over 90% of patients without the need for adaptive planning. However, OAR constraints are not met in 40% of delivered fractions despite meeting all dose constraints at the time of treatment planning. Online dose prediction and, if indicated, adaptive radiotherapy can optimize this to allow for improved OAR protection and potentially allow for further reductions in the PTV expansion while maintaining adequate CTV coverage.

Intensity-modulated brachytherapy for vaginal cancer.

This study aimed to evaluate the dose modulation potential of static and dynamic steel-shielded applicators using the Geant4 Application for Emission Tomography (GATE) Monte Carlo code for the treatment of vaginal cancer. The GATE TOOLKIT (version 9.0) was used to simulate vaginal cancer intensity-modulated brachytherapy (IMBT) in a pelvic water-equivalent phantom. IMBT performance of a multichannel static and single-channel dynamic steel-shielded applicator was compared to that of a conventional multichannel Plexiglas applicator. DoseActors were defined to calculate the absorbed dose and attached to the voxelized target and organs at risk (OARs). 60Co and 192Ir high-dose-rate seeds were used as irradiation sources. Dynamic IMBT decreased the D2cc of the rectum and bladder by 28.67 and 28.11% using the 60Co source and by 40.00 and 36.34% using the 192Ir source, respectively. Static IMBT decreased the D2cc for the rectum and bladder by 11.69 and 9.29% using the 60Co source and by 22.21 and 17.71% using the 192Ir source, respectively. In contrast, absorbed dose parameters (D5, D90, and D100) for the target in the three techniques showed a mean relative variation of 0.96% (0.00-7.49%) for both sources. Static and dynamic IMBT using steel-shielded applicators provided relatively better OAR protection while maintaining similar target coverage in the treatment of vaginal cancer.

Radiobiological Comparison of Acuros External Beam and Anisotropic Analytical Algorithm on Esophageal Carcinoma Radiotherapy Treatment Plans.

ObjectiveThe present study aimed to investigate the dose differences and radiobiological assessment between Anisotropic Analytical Algorithm (AAA) and Acuros External Beam (AXB) with its 2 calculation models, namely, dose-to-water (AXB-Dw) and dose-to-medium (AXB-Dm), on esophageal carcinoma radiotherapy treatment plans.Materials and methodsThe AXB-Dw and AXB-Dm plans were generated by recalculating the initial 66 AAA plans using the AXB algorithm with the same monitor units and beam parameters as those in the original plan. The dosimetric and radiobiological assessment parameters were calculated for the planning target volume (PTV) and organs at risk (OARs). The gamma agreement for the PTV and the correlation between it and the volume of the air cavity and bone among the different algorithms were compared simultaneously. The dose discrepancy between the theoretical calculation and treatment planning system (TPS) when switching from AXB-Dm to AXB-Dw was analyzed according to the composition of the structures.ResultsThe PTV dose of AXB-Dm plans was significantly smaller than that of the AAA and AXB-Dw plans (P < .05), except for D2. The difference values for AAA vs AXB-Dm (∆Dx,(AAA-AXB,Dm)) and AXB-Dw vs AXB-Dm (∆Dx,(AXB,Dw-AXB,Dm)) were 1.94% [1.27%, 2.64%] and 1.95% [1.56%, 2.27%], respectively. For the spinal cord and heart, there were obvious differences between the AAA vs AXB-Dm (spinal cord: 1.15%, heart: 2.89%) and AXB-Dw vs AXB-Dm (spinal cord: 1.88%, heart: 3.25%) plans. For the lung, the differences between AAA vs AXB-Dm and AAA vs AXB-Dw were significantly larger than those of AXB-Dm vs AXB-Dw. Compared to the case of AAA and AXB-Dw, the decrease in biologically effective dose (BED10, ) of AXB-Dm due to dose non-uniformity exceeded 6.5%, even for a small . The average values of equivalent uniform dose in the AAA, AXB-Dw, and AXB-Dm plans were 52.03±.39 Gy, 52.24 ± .81 Gy, and 51.13 ± .47 Gy, respectively. The tumor control probability (TCP) results for PTV in the AAA, AXB-Dw, and AXB-Dm plans were 62.29 ± 1.57%, 62.82 ± 1.69%, and 58.68±1.88%, respectively. With the 2%/2 mm and 3%/3 mm acceptance criteria, the mean values of , , and were 87.24, 63.3, and 64.81% vs 97.86, 91.77, and 89.25%, respectively. The dose discrepancy between the theoretical calculation and TPS when switching from AXB-Dm to AXB-Dw was approximately 1.63%.ConclusionsThe AAA and AXB-Dw algorithms overestimated the radiobiological parameters when the tumor particularly consisted of nonuniform tissues. A relatively small dose difference could cause a significant reduction in the corresponding TCP. Dose distribution algorithms should be carefully chosen by physicists and oncologists to improve tumor control, as well as to optimize OARs protection.

SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes

PurposeTo demonstrate dosimetry benefits and report clinical outcomes of stereotactic magnetic resonance (MR)-guided online adaptive radiotherapy (SMART) of abdominopelvic lymphatic oligometastases. Patients & MethodsProspective registry data of 26 patients with 31 oligoprogressive lymphatic metastases (1–2 lesions) who received SMART between April 2020 and April 2021 was analyzed. Prostate cancer was the most common histology (69%). Most patients (63%) had received previous abdominopelvic radiotherapy (RT). SMART was delivered in 3–7 fractions based on planning target volume (PTV) location and previous dose exposures. For SMART, the baseline plan was recalculated on daily 3D MR-imaging (predicted plan), and plan adaptation was mandatory in case of planning objective violations. ResultsPlan adaptation was mostly performed due to violation of planning objectives in the predicted plan (134/140 fractions, 96%) and significantly improved plan dosimetry: (1) PTV coverage was increased (predicted: median 89%, adapted: median 95%, p < 0.001), (2) organs-at-risk (OAR) overdoses were reduced (predicted: 27/140 (19%), adapted: 1/140 (1%), p < 0.001) and (3) PTV overdoses were reduced (predicted: 21/140 (15%), adapted: 1/140 (1%), p < 0.001). After a median follow-up of 9.8 months, one patient had in-field tumor progression and twelve patients had out-field tumor progression (at 6 months: progression-free survival: 63% [46–88%], local control rate: 97% [90–100%]). Treatment was tolerated well and no grade ≥3 toxicity was reported. ConclusionSMART improves target volume coverage and yields superior OAR protection compared to non-adaptive radiotherapy, thus representing an innovative approach to challenging cases, such as repeated radiotherapy.

Automatic Radiotherapy Planning for Glioblastoma Radiotherapy With Sparing of the Hippocampus and nTMS-Defined Motor Cortex.

BackgroundNavigated transcranial magnetic stimulation (nTMS) of the motor cortex has been successfully implemented into radiotherapy planning by a number of studies. Furthermore, the hippocampus has been identified as a radiation-sensitive structure meriting particular sparing in radiotherapy. This study assesses the joint protection of these two eloquent brain regions for the treatment of glioblastoma (GBM), with particular emphasis on the use of automatic planning.Patients and MethodsPatients with motor-eloquent brain glioblastoma who underwent surgical resection after nTMS mapping of the motor cortex and adjuvant radiotherapy were retrospectively evaluated. The radiotherapy treatment plans were retrieved, and the nTMS-defined motor cortex and hippocampus contours were added. Four additional treatment plans were created for each patient: two manual plans aimed to reduce the dose to the motor cortex and hippocampus by manual inverse planning. The second pair of re-optimized plans was created by the Auto-Planning algorithm. The optimized plans were compared with the “Original” plan regarding plan quality, planning target volume (PTV) coverage, and sparing of organs at risk (OAR).ResultsA total of 50 plans were analyzed. All plans were clinically acceptable with no differences in the PTV coverage and plan quality metrics. The OARs were preserved in all plans; however, overall the sparing was significantly improved by Auto-Planning. Motor cortex protection was feasible and significant, amounting to a reduction in the mean dose by >6 Gy. The dose to the motor cortex outside the PTV was reduced by >12 Gy (mean dose) and >5 Gy (maximum dose). The hippocampi were significantly improved (reduction in mean dose: ipsilateral >6 Gy, contralateral >4.6 Gy; reduction in maximum dose: ipsilateral >5 Gy, contralateral >5 Gy). While the dose reduction using Auto-Planning was generally better than by manual optimization, the radiated total monitor units were significantly increased.ConclusionConsiderable dose sparing of the nTMS-motor cortex and hippocampus could be achieved with no disadvantages in plan quality. Auto-Planning could further contribute to better protection of OAR. Whether the improved dosimetric protection of functional areas can translate into improved quality of life and motor or cognitive performance of the patients can only be decided by future studies.

Comparison of dosimetric parameters and three-dimensional dosimetric verification of three intensity-modulated radiotherapy plans for thymoma based on the dose-volume histogram and ArcCHECK-3DVH system

Objective: To compare the dosimetric parameters of step-shoot intensity-modulated radiotherapy (sIMRT), dynamic intensity-modulated radiotherapy (dIMRT), and volume-modulated arc therapy (VMAT) in thymoma and to study the feasibility of the ArcCHECK-3DVH system in three intensity-modulated radiotherapy plans to choose a more appropriate intensity-modulated radiotherapy for thymoma. Materials and Methods: Seventeen patients with thymoma were enrolled in this study. Treatment plans of sIMRT, dIMRT, and VMAT for each patient were based on the Monaco treatment planning system (TPS). Dosimetric verification was performed via the ArcCHECK-3DVH system. We compared and analyzed the 3D γ pass rates of the TPS dose calculation and ArcCHECK-3DVH system dose reconstruction with the three gamma criteria (3 mm/3%, 2 mm/2%, and 1 mm/1%) with a threshold of 10%. Dose-volume histogram analysis was used to compare the dose parameters for target volumes, and organs at risk (OARs), such as D98%, D50%, D2%, Dmax, V20, and V5. Monitor units (MUs) and delivery time were also compared. Results: There were significant differences in the three intensity-modulated radiotherapy plans. For target volume, VMAT showed the highest planning target volume (PTV) D98% and the lowest PTV D50% compared with sIMRT or dIMRT. The PTV D2% of VMAT was lower than that of sIMRT and higher than that of dIMRT, and VAMT demonstrated the highest conformity index and MU, lowest homogeneity index, and shortest treatment delivery time. For the OARs, VMAT is not inferior to sIMRT and dIMRT in OARs protection. For the dosimetric verification, the entire area, PTV, lungs, heart, and spinal cord of VMAT showed the highest γ pass rates than the other two techniques under the gamma 3 mm/3% criteria, which was even more pronounced when the stricter gamma criteria of 2 mm/2% and 1 mm/1% were applied. Conclusion: VMAT can be applied to radiotherapy of thymoma, and the accuracy of treatment plan execution can be guaranteed through the ArcCHECK-3DVH system.

Significance of ovarian transposition in the preservation of ovarian function for young cervical cancer patients undergoing postoperative volumetric modulated radiotherapy.

BackgroundThis paper aimed to evaluate the effectiveness of ovarian transposition (OT) and the dose constraint for preserving ovarian function in young cervical cancer patients who underwent postoperative volumetric modulated arc therapy (VMAT).MethodsA retrospective analysis was conducted of young cervical cancer patients who accepted postoperative VMAT in the Affiliated Cancer Hospital of Nanjing Medical University from September 2015 to September 2018. VMAT plans for OT and non-OT patients were compared, and the patients’ ovarian function was followed up. The transposed position of the ovaries and the radiation dose constraint were further explored using a receiver operator characteristic (ROC) curve.ResultsA total of 51 young patients (age ≤40 years) were included in the study, 32 of whom underwent OT and 19 of whom did not. For these OT and non-OT patients, the homogeneity index (HI), conformity index (CI), organs at risk (OARs), average number of monitor units (MUs), and mean treatment time were similar and showed no statistically significant difference (P≥0.05). Through follow-up studies, the number of patients with preserved ovarian function was found to be 22 (out of 32) and 0 (out of 19) in the OT and non-OT patients, respectively. The minimal distance for preserving ovarian function was determined as 2.1 cm between the center of a transposed ovary and the planning target volume (PTV) margin. The optimal limited radiation doses were estimated as maximum dose (Dmax) 9.8 Gy and mean dose (Dmean) 4.6 Gy, respectively.ConclusionsOT shows no negative effects on dose distribution, target region conformity, protection of OARs, or treatment efficacy and is therefore a reliable method in the preservation of ovarian function for young cervical cancer patients undergoing postoperative radiotherapy using the VMAT technique. Specifically, when the distance between the center of a transposed ovary and the PTV margin is more than 2.1 cm, and the radiation dose is limited to a Dmax of less than 9.8 Gy and a Dmean of less than 4.6 Gy, the function of transposed ovaries may be preserved.

Systematic quantitative evaluation of Plan-IQ for intensity-modulated radiation therapy after modified radical mastectomy

Radiotherapy (RT) is one of the main treatment strategies of breast cancer. It is challenging to design RT plans that can completely cover the target area while protecting organs at risk (OAR). The Plan-IQ feasibility tool can estimate the best sparing dose of OAR before optimizing the Plan. A systematic quantitative evaluation of the quality change of intensity-modulated radiation therapy (IMRT) using the Plan-IQ feasibility tool was performed for modified radical mastectomy in this study. We selected 50 patients with breast cancer treated with IMRT. All patients received the same dose in the planning target volume (PTV). The plans are categorized into two groups, with each patient having one plan in each group: the clinically accepted normal plan group (NP group) and the repeat plan group (RP group). An automated planning strategy was generated using a Plan-IQ feasibility dose volume histogram (FDVH) in RP group. These plans were assessed according to the dosimetry parameters. A detailed scoring strategy was based on the RTOG9804 report and 2018 National Comprehensive Cancer Network guidelines, combined with clinical experience. PTV coverage in both groups was achieved at 100% of the prescribed dose. Except for the thyroid coverage, the dose limit of organs at risk (OAR) in RP group was significantly better than that in NP group. In the scoring analysis, the total scores of RP group decreased compared to that of NP group (P < 0.05), and the individual scores of PTV and OAR significantly changed. PTV scores in RP group decreased (P < 0.01); however, OAR scores improved (P < 0.01). The Plan-IQ FDVH was useful for evaluating a class solution for IMRT planning. Plan-IQ can automatically help physicians design the best OAR protection plan, which sacrifices part of PTV, but still meets clinical requirements.

Comparison of Dosimetric Benefits of Three Precise Radiotherapy Techniques in Nasopharyngeal Carcinoma Patients Using a Priority-Classified Plan Optimization Model.

IntroductionAlthough intensity-modulated radiotherapy (IMRT), volumetric-modulated arc therapy (VMAT) and tomotherapy (TOMO) are broadly applied for nasopharyngeal carcinoma (NPC), the best technique remains unclear. Therefore, this study was conducted to address this issue.MethodsThe priority-classified plan optimization model was applied to IMRT, VMAT and TOMO plans in forty NPC patients according to the latest international guidelines. And the dosimetric parameters of planning target volumes (PTVs) and organs at risk (OARs) were compared among these three techniques. The Friedman M test in SPSS software was applied to assess significant differences.ResultsThe median PGTVnx coverage of IMRT was the lowest (93.5%, P < 0.001) for all T categories. VMAT was comparable to TOMO in OARs clarified as priority I and II, and both satisfied the prescribed requirement. IMRT resulted in a relatively high dose for V25 and V30. Interestingly, subgroup analysis showed that the median PTV coverage of the three techniques was no less than 95% in the early T stage. The heterogeneity index (HI) of PGTVnx in VMAT was better than that in IMRT (P = 0.028). Compared to TOMO, VMAT showed a strong ability to protect eyesight and decrease low-dose radiation volumes. In the advanced T stage subgroup, TOMO numerically achieved the highest median PGTVnx coverage volume compared with VMAT and IMRT (93.61%, 91% and 90%, respectively). The best CI and HI of PCTV-1 were observed in TOMO. Furthermore, TOMO was better than VMAT for sparing the brain stem, spinal cord and temporal lobes (all P < 0.05). However, the median V5, V10, V15, V20 and V25 were significantly higher with TOMO than with VMAT (all P < 0.05).ConclusionIn the early T stage, VMAT provides a similar dose coverage and protection of OARs to IMRT, and there are no obvious advantages to choosing TOMO for NPC patients in the early T stage. TOMO may be recommended for patients in the advanced T stage due as it provides the largest dose coverage of PGTVnx and the best protection of the brain stem, spinal cord and temporal lobes. Additionally, more randomized clinical trials are needed for further clarification.

Model-based comparison of organ at risk protection between VMAT and robustly optimised IMPT plans

The comparison between intensity-modulated proton therapy (IMPT) and volume-modulated arc therapy (VMAT) plans, based on models of normal tissue complication probabilities (NTCP), can support the choice of radiation modality. IMPT irradiation plans for 50 patients with head and neck tumours originally treated with photon therapy have been robustly optimised against density and setup uncertainties. The dose distribution has been calculated with a Monte Carlo (MC) algorithm. The comparison of the plans was based on dose-volume parameters in organs at risk (OARs) and NTCP-calculations for xerostomia, sticky saliva, dysphagia and tube feeding using Langendijk's model-based approach. While the dose distribution in the target volumes is similar, the IMPT plans show better protection of OARs. Therefore, it is not the high dose confirmation that constitutes the advantage of protons, but it is the reduction of the mid-to-low dose levels compared to photons. This work investigates to what extent the advantages of proton radiation are beneficial for the patient's post-therapeutic quality of life (QoL). As a result, approximately one third of the patients examined benefit significantly from proton therapy with regard to possible late side effects. Clinical data is needed to confirm the model-based calculations.

Hybrid volumetric modulated arc therapy for hypofractionated radiotherapy of breast cancer: a\xa0treatment planning study

PurposeThis study aims to evaluate the best possible practice using hybrid volumetric modulated arc therapy (H-VMAT) for hypofractionated radiation therapy of breast cancer. Different combinations of H‑VMAT—a combination of three-dimensional radiotherapy (3D-CRT) and VMAT—were analyzed regarding planning target volume (PTV), dose coverage, and exposure to organs at risk (OAR).MethodsPlanning computed tomography scans were acquired in deep-inspiration breath-hold. A total of 520 treatment plans were calculated and evaluated for 40 patients, comprising six different H‑VMAT plans and a 3D-CRT plan as reference. H‑VMAT plans consisted of two treatment plans including 3D-CRT and VMAT. During H‑VMAT planning, the use of hard wedge filters (HWF) and beam energies were varied. The reference plans were planned with mixed beam energies and the inclusion/omission of HWF.ResultsCompared to the reference treatment plans, all H‑VMAT plans showed consistently better PTV dose coverage, conformity, and homogeneity. Additionally, OAR protection was significantly improved with several H‑VMAT combinations (p < 0.05). The comparison of different H‑VMAT combinations showed that inclusion of HWF in the base plan had a negative impact on PTV dose coverage, conformity, and OAR exposure. It also increased the planned monitor units and beam-on time. Advantages of using lower beam energies (6-MV photons) in both the base plan and in the VMAT supplementary dose were observed.ConclusionThe H‑VMAT technique is an effective possibility for generating homogenous and conformal dose distributions. With the right choice of H‑VMAT combination, superior OAR protection is achieved compared to 3D-CRT.